Metabolic & Weight ManagementIn StockMetabolic & Weight Management
Cagrilintide
Also known as: AM833, Long-acting amylin analog
Long-acting synthetic amylin analog under clinical investigation; used in amylin/calcitonin-receptor research.
Cagrilintide (AM833) is a long-acting synthetic analog of human amylin, developed by Novo Nordisk as an investigational compound.
It is structurally derived from amylin with modifications that extend its plasma half-life and improve its stability in solution.In the research literature, Cagrilintide is studied primarily for its activity at the amylin receptor complex (composed of the calcitonin receptor with RAMP1, RAMP2, or RAMP3).
It has frequently been investigated in combination with semaglutide, reflecting the scientific interest in dual amylin-plus-GLP-1 signaling for metabolic research.
Research applications
- Amylin receptor complex pharmacology (AMY1, AMY2, AMY3)
- Calcitonin-receptor signaling research
- Combination research with GLP-1 receptor agonists
- Satiety and gastric-emptying signaling models
- Long-acting peptide formulation research
Technical profile
- Net content
- 10 mg
- Molecular formula
- See Certificate of Analysis
- Molecular weight
- ~3800 g/mol
- CAS
- 1415456-99-3
- Sequence
- Modified 37-amino-acid amylin analog with pyroglutamate N-terminus and C20 fatty acid
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Cagrilintide is a long-acting amylin analogue that activates amylin receptors to reduce appetite and food intake. It is studied in combination with incretin-based therapies for enhanced weight management and metabolic outcomes.
